| Literature DB >> 21941606 |
Saleh A Bakheet1, Sabry M Attia.
Abstract
We used the bone marrow DNA strand breaks, micronucleus formations, spermatocyte chromosomal aberrations, and sperm characteristic assays to investigate the chromosomal instability in somatic and germinal cells of diabetic rats treated with multiple doses of naringin. The obtained results revealed that naringin was neither cytotoxic nor genotoxic for the rats at all tested doses. Moreover, naringin significantly reduced the diabetes-induced chromosomal instability in somatic and germinal cells in a dose-dependent manner. In addition, diabetes induced marked biochemical alterations characteristic of oxidative stress including enhanced lipid peroxidation, accumulation of oxidized glutathione, reduction in reduced glutathione, and accumulation of intracellular reactive oxygen species. Treatment with naringin ameliorated these biochemical markers dose-dependently. In conclusion, naringin confers an appealing protective effect against diabetes-induced chromosomal instability towards rat somatic and germinal cells which might be explained partially via diminishing the de novo free radical generation induced by hyperglycemia. Thus, naringin might be a good candidate to reduce genotoxic risk associated with hyperglycemia and may provide decreases in the development of secondary malignancy and abnormal reproductive outcomes risks, which seems especially important for diabetic patients.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21941606 PMCID: PMC3176618 DOI: 10.1155/2011/365292
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
DNA strand breaks in bone marrow of nondiabetic and diabetic rats 24 hours after the last treatment with the indicated doses of naringin (4 weeks exposures, spaced 24 hours apart) (mean ± SD).
| Treatment groups (mg/kg) | Tail length ( | Tail DNA (%) | Tail moment (arbitrary unit) | Olive tail moment (arbitrary units) |
|---|---|---|---|---|
| Nondiabetic control | 14.0 ± 4.8 | 5.98 ± 1.15 | 1.96 ± 0.61 | 4.78 ± 1.23 |
| Nondiabetic + naringin (25) | 12.6 ± 4.77 | 5.76 ± 1.52 | 2.12 ± 0.43 | 4.14 ± 0.56 |
| Nondiabetic + naringin (50) | 11.8 ± 4.71 | 4.82 ± 1.76 | 1.98 ± 0.23 | 3.20 ± 0.73 |
| Diabetes | 27.2 ± 4.91* | 14.2 ± 3.39* | 4.72 ± 0.54** | 9.44 ± 2.03* |
| Diabetes + naringin (25) | 18.6 ± 4.33a | 8.08 ± 1.54b | 2.98 ± 0.85a | 5.82 ± 1.27b |
| Diabetes + naringin (50) | 15.8 ± 3.96b | 6.97 ± 1.53b | 2.24 ± 0.7b | 4.32 ± 1.18b |
*P < 0.05 and **P < 0.01 versus nondiabetic control (Kruskal-Wallis test followed by Dunn's multiple comparisons test). a P < 0.05 and b P < 0.01 versus diabetes alone (Mann-Whitney U test).
Frequencies of micronucleated polychromatic erythrocytes (% MNPCE) and mitotic activity (% PCE) in bone marrow of nondiabetic and diabetic rats 24 hours after the last treatment with the indicated doses of naringin (4 weeks exposures, spaced 24 hours apart) (mean ± SD).
| Treatment groups (mg/kg) | % MNPCE (mean ± SD) | % PCE (mean ± SD) |
|---|---|---|
| Nondiabetic control | 0.32 ± 0.08 | 48.4 ± 1.81 |
| Nondiabetic + naringin (25) | 0.30 ± 0.07 | 48.2 ± 2.16 |
| Nondiabetic + naringin (50) | 0.28 ± 0.08 | 49.0 ± 1.41 |
| Diabetes | 0.92 ± 0.13** | 45.6 ± 3.97 |
| Diabetes + naringin (25) | 0.60 ± 0.12a | 47.0 ± 2.54 |
| Diabetes + naringin (50) | 0.44 ± 0.11b | 47.4 ± 2.40 |
**P < 0.01 versus nondiabetic control (Kruskal-Wallis test followed by Dunn's multiple comparisons test). a P < 0.05 and b P < 0.01 versus diabetes alone (Mann-Whitney U test).
Frequency of spermatocyte chromosomal aberrations in testes of nondiabetic and diabetic rats 24 hours after the last treatment with the indicated doses of naringin (4 weeks exposures, spaced 24 hours apart) (mean ± SD).
| Treatment groups (mg/kg) | Different structural chromosomal aberrations screened | Total chromosomal aberrations (%) | ||||
|---|---|---|---|---|---|---|
| X-Y univalents | Autosomal univalents | F/B | Polyploidy | MV | ||
| Nondiabetic control | 7 | 4 | 2 | 0 | 1 | 2.8 ± 0.44 |
| Nondiabetic + naringin (25) | 6 | 3 | 1 | — | 1 | 2.4 ± 0.89 |
| Nondiabetic + naringin (50) | 5 | 6 | 1 | 0 | 1 | 2.6 ± 0.89 |
| Diabetes | 22 | 18 | 3 | 2 | 3 | 9.60 ± 1.51* |
| Diabetes + naringin (25) | 13 | 10 | 2 | 1 | 1 | 5.40 ± 1.81a |
| Diabetes + naringin (50) | 6 | 5 | 2 | 2 | 1 | 3.20 ± 1.09b |
*P < 0.05, versus nondiabetic control (Kruskal-Wallis test followed by Dunn's multiple comparisons test). a P < 0.05 and b P < 0.01 versus diabetes alone (Mann-Whitney U test). F: fragments; B: breaks; MV: multivalents having a chain of four chromosomes.
Frequencies of sperm count, abnormalities, ROS, GSSG, GSH, GSSG/GSH ratio, and MDA of nondiabetic and diabetic rats 24 hours after the last treatment with the indicated doses of naringin (4 weeks exposures, spaced 24 hours apart) (mean ± SD).
| Treatment groups (mg/kg) | Counts (×106/couda epididymis) | Abnormal sperm (%) | MDA (nmol/mg protein) | GSH ( | GSSG ( | GSH/GSSG ratio | ROS (% of control) |
|---|---|---|---|---|---|---|---|
| Nondiabetic control | 46.8 ± 6.7 | 2.2 ± 0.8 | 12.6 ± 1.8 | 1.8 ± 0.4 | 0.26 ± 0.05 | 7.4 ± 2.5 | 100.0 ± 7.4 |
| Nondiabetic + naringin (25) | 49.0 ± 5.7 | 1.8 ± 0.8 | 11.4 ± 3.2 | 1.9 ± 0.4 | 0.24 ± 0.05 | 8.1 ± 2.0 | 95.4 ± 8.5 |
| Nondiabetic + naringin (50) | 51.0 ± 7.3 | 1.6 ± 0.54 | 10.4 ± 2.7 | 2.2 ± 0.5 | 0.25 ± 0.07 | 8.3 ± 2.8 | 93.2 ± 9.3 |
| Diabetes | 34.8 ± 3.3* | 6.4 ± 1.3* | 19.6 ± 3.7* | 0.8 ± 0.2* | 0.36 ± 0.04* | 2.4 ± 0.8 | 160.8 ± 15.5* |
| Diabetes + naringin (25) | 41.0 ± 4.2a | 4.6 ± 0.5a | 13.6 ± 3.5b | 1.5 ± 0.18b | 0.26 ± 0.05a | 6.0 ± 1.5b | 125.4 ± 14.9b |
| Diabetes + naringin (50) | 46.0 ± 3.6b | 2.2 ± 0.8b | 10.8 ± 2.6b | 1.8 ± 0.15b | 0.22 ± 0.05b | 8.5 ± 2.1b | 106.4 ± 8.7b |
*P < 0.05 versus nondiabetic control (Kruskal-Wallis test followed by Dunn's multiple comparisons test), a P < 0.05, b P < 0.01 versus diabetes alone (Mann-Whitney U test). MDA: malondialdehyde; GSH: reduced glutathione; GSSG: oxidized glutathione; ROS: reactive oxygen species.